GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

Topchoice Medical Co 600763.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

36.92

-1.86%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥2.91bn

FY2016FY2025

Net income

CN¥501.9m

FY2016FY2025

Free cash flow

CN¥564.5m

FY2016FY2025

Shareholders' equity

CN¥4.23bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥2.91bnCN¥2.87bnCN¥2.85bnCN¥2.72bnCN¥2.78bnCN¥2.09bnCN¥1.93bnCN¥1.55bnCN¥1.18bnCN¥878.8m
Gross profitCN¥1.13bnCN¥1.11bnCN¥1.10bnCN¥1.11bnCN¥1.28bnCN¥943.0mCN¥881.6mCN¥669.3mCN¥488.0mCN¥363.3m
Research and developmentCN¥61.2mCN¥59.0mCN¥55.6mCN¥54.0mCN¥59.1mCN¥40.1mCN¥22.1mCN¥23.0mCN¥15.8mCN¥15.0m
Operating incomeCN¥713.9mCN¥698.6mCN¥711.9mCN¥735.0mCN¥974.9mCN¥650.3mCN¥638.9mCN¥439.4mCN¥285.0mCN¥176.6m
Net incomeCN¥501.9mCN¥501.4mCN¥500.4mCN¥548.3mCN¥702.8mCN¥492.6mCN¥466.1mCN¥332.1mCN¥216.6mCN¥136.2m
Diluted earnings per share1.121.121.561.712.201.531.461.040.670.42

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥6.04bnCN¥6.18bnCN¥6.01bnCN¥5.15bnCN¥4.95bnCN¥3.06bnCN¥2.66bnCN¥2.13bnCN¥1.79bnCN¥1.29bn
Cash and short-term investments—CN¥622.0mCN¥594.5mCN¥630.3mCN¥844.0mCN¥674.1mCN¥483.0mCN¥350.4mCN¥559.8mCN¥283.2m
Total liabilitiesCN¥1.47bnCN¥1.82bnCN¥1.88bnCN¥1.54bnCN¥1.81bnCN¥716.0mCN¥690.1mCN¥684.9mCN¥695.3mCN¥387.4m
Debt—CN¥1.31bnCN¥1.27bnCN¥1.15bnCN¥1.30bnCN¥285.3mCN¥380.4mCN¥454.8mCN¥500.0mCN¥260.0m
Shareholders' equityCN¥4.23bnCN¥4.03bnCN¥3.81bnCN¥3.31bnCN¥2.88bnCN¥2.15bnCN¥1.79bnCN¥1.32bnCN¥992.6mCN¥817.7m
Shares outstanding447m447m320m320m320m321m320m319m323m321m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥810.7mCN¥763.4mCN¥840.0mCN¥670.0mCN¥939.4mCN¥708.5mCN¥647.8mCN¥469.4mCN¥346.6mCN¥161.0m
Capital spending−CN¥246.2m−CN¥332.1m−CN¥508.9m−CN¥421.5m−CN¥367.3m−CN¥170.5m−CN¥125.8m−CN¥240.6m−CN¥68.7m−CN¥98.4m
Free cash flowCN¥564.5mCN¥431.3mCN¥331.1mCN¥248.5mCN¥572.1mCN¥538.0mCN¥522.0mCN¥228.9mCN¥277.9mCN¥62.6m
Dividends paid−CN¥208.9m−CN¥149.9m−CN¥11.2m−CN¥6.7m−CN¥12.9m−CN¥21.1m−CN¥22.6m−CN¥35.8m−CN¥54.9m−CN¥15.7m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥830.8mCN¥755.3mCN¥622.9mCN¥841.8mCN¥703.8mCN¥744.6mCN¥640.7mCN¥822.5m
Gross profitCN¥349.8mCN¥331.4mCN¥170.5mCN¥364.5mCN¥261.1mCN¥329.2mCN¥172.8mCN¥357.9m
Operating incomeCN¥255.8mCN¥237.7mCN¥35.8mCN¥261.3mCN¥181.1mCN¥240.1mCN¥28.6mCN¥262.3m
Net incomeCN¥271.5mCN¥186.9m−CN¥11.6mCN¥192.3mCN¥137.2mCN¥183.9mCN¥3.2mCN¥188.5m
Diluted earnings per share0.610.42-0.030.430.310.410.010.42
Cash from operations———CN¥329.0mCN¥208.0mCN¥147.0mCN¥116.0mCN¥313.0m
Capital spending−CN¥69.0m−CN¥49.0m−CN¥27.0m−CN¥70.0m−CN¥87.0m−CN¥60.0m−CN¥51.0m−CN¥72.0m
Free cash flow———CN¥259.0mCN¥121.0mCN¥87.0mCN¥65.0mCN¥241.0m
Total assetsCN¥5.99bnCN¥6.24bnCN¥6.04bnCN¥6.28bnCN¥6.16bnCN¥6.26bnCN¥6.18bnCN¥6.22bn
Cash and short-term investments———CN¥578.5mCN¥483.2mCN¥598.8mCN¥622.0mCN¥597.9m
Debt———CN¥339.8mCN¥50.0mCN¥294.9mCN¥249.1mCN¥259.0m
Shareholders' equityCN¥4.14bnCN¥4.42bnCN¥4.23bnCN¥4.34bnCN¥4.15bnCN¥4.21bnCN¥4.03bnCN¥4.13bn

Financial ratios

Data as of 27 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Gross margin38.6%38.5%38.5%40.8%46.1%45.2%—
Operating margin24.5%24.3%25.0%27.0%35.1%31.1%—
Net margin17.2%17.4%17.6%20.2%25.3%23.6%—
Return on equity11.9%12.4%13.1%16.6%24.4%22.9%—
Return on assets8.3%8.1%8.3%10.6%14.2%16.1%—
Free cash flow yield7.1%7.3%12.6%10.2%12.2%8.2%—
Revenue growth1.4%1.0%4.7%-2.2%33.2%8.1%—
Earnings growth0.1%0.2%-8.7%-22.0%42.7%5.7%—
Current ratio1.49x1.68x1.40x2.33x1.63x1.82x—
Debt to equity—0.06x0.07x0.01x0.10x0.13x0.18x
Equity ratio70.1%65.2%63.5%64.2%58.1%70.2%—
Interest coverage19.92x13.32x11.63x13.17x28.12x27.94x—
R&D as a share of sales2.1%2.1%2.0%2.0%2.1%1.9%—
Buybacks as a share of market value-0.0%-39.9%0.0%-0.0%0.5%-0.5%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue2.3%6.9%14.3%
Operating income-1.0%1.9%15.6%
Net income-2.9%0.4%15.0%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin38.6%39.1%41.1%41.7%
Operating margin24.4%25.2%27.6%27.5%
Net margin17.3%18.1%20.0%20.1%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings35.839.634.963.764.6128.850.232.634.456.5
Price to sales6.26.96.112.816.330.412.17.06.38.8

Dividends and splits

Per share, in the currency the company pays

Paid for 2 years. Last went ex-dividend on 18 Jun 2025.

FY2025FY2024FY2018FY2017
Paid in the year0.450.4360.0210.093
  • 1.401-for-1 split · 5 Jul 2024
  • 2-for-1 split · 4 Dec 2015
  • 6-for-5 split · 3 Jun 1997

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.